Abstract Number: PP17 • ACR Convergence 2026
What I Was Never Told: A Patient Perspective on Systemic Sclerosis Renal Crisis
Background/Purpose: In 2018, I began experiencing progressive weakness, swelling, fatigue, and loss of function that steadily impacted my daily life and independence. After months of…Abstract Number: 0712 • ACR Convergence 2026
Gout Flare Burden and Cardiorenal Outcomes With Glucagon-Like Peptide-1 Receptor Agonists Versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus and Gout: A Propensity-Matched Retrospective Study
Background/Purpose: GLP-1 receptor agonists (GLP-1 RAs) have established cardiovascular and renal benefits in T2DM and demonstrate uricosuric and anti-inflammatory properties in preclinical studies that may…Abstract Number: 1263 • ACR Convergence 2026
Early Identification of Proteinuria in Lupus: Diagnostic Performance of First Morning, Random, and 24-Hour Urine Protein Measurements
Background/Purpose: Early detection of proteinuria can identify kidney involvement in systemic lupus erythematosus (SLE), providing an opportunity for earlier interventions to improve outcomes and survival1,2.…Abstract Number: 1997 • ACR Convergence 2026
Dysregulation of sphingosine-1-phosphate signaling in systemic lupus erythematosus and its therapeutic implications
Background/Purpose: The etiology of systemic lupus erythematosus (SLE) remains incompletely understood, and current therapies largely rely on broad-spectrum immunosuppressants. Sphingosine-1-phosphate (S1P) is a bioactive lipid…Abstract Number: 0713 • ACR Convergence 2026
Gout in Advanced Chronic Kidney Disease: High Prevalence, Low Target Attainment, and Association with Mortality – Real-World Evidence for a Complex Comorbidity
Background/Purpose: Gout is common in advanced chronic kidney disease (CKD), yet evidence guiding urate-lowering therapy (ULT) in this population remains limited. Challenges include impaired renal…Abstract Number: 1267 • ACR Convergence 2026
Histological Evolution and Clinical Impact of Repeat Renal Biopsy in Lupus Nephritis
Background/Purpose: Lupus nephritis shows temporal heterogeneity in histological class and chronic damage, often independent of clinical and laboratory parameters [1]. We evaluated histological class transitions,…Abstract Number: 2000 • ACR Convergence 2026
Inflammation-independent Remodeling Defines a Renal Disease Axis in Systemic Lupus Erythematosus
Background/Purpose: Renal involvement in systemic lupus erythematosus (SLE) is heterogeneous, and mechanisms underlying renal injury extend beyond canonical interferon-driven inflammation. We hypothesized that remodeling-associated biology…Abstract Number: 0923 • ACR Convergence 2026
The Disparate Effect of Statins on eGFR in Systemic Lupus Erythematosus
Background/Purpose: Beyond lipid-lowering, statins may preserve kidney function through anti-inflammatory effects, improved endothelial function, and reduced podocyte cell death. The 2024 KDIGO guidelines recommend statins…Abstract Number: 1285 • ACR Convergence 2026
Renal Tubular Complement C9 Deposition is Linked to Tubulointerstitial Fibrosis and Progression to Chronic Kidney Disease in Lupus Nephritis: a two-center study.
Background/Purpose: Lupus nephritis (LN) is a major cause of chronic kidney disease (CKD) and end-stage renal disease in systemic lupus erythematosus. Emerging data suggest that intrarenal complement…Abstract Number: 2131 • ACR Convergence 2026
Clinical Outcomes by Glucocorticoid Duration in Individuals with Granulomatosis with Polyangiitis and Microscopic Polyangiitis Treated with Avacopan in a Real-World Setting in Two Large Healthcare Systems
Background/Purpose: The ADVOCATE trial that led to the approval of avacopan for the treatment of severe active granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)…Abstract Number: 0933 • ACR Convergence 2026
Microvascular Antiphospholipid Syndrome Is Associated with Subclinical Renal Involvement and Long-Term Kidney Function Decline
Background/Purpose: Renal involvement in antiphospholipid syndrome (APS) may be under-recognized, particularly in patients without overt renal thrombosis or severe reduction in estimated glomerular filtration rate…Abstract Number: 1298 • ACR Convergence 2026
Urinary Complement Activation Products and Soluble CD163 as Lupus Nephritis Biomarkers
Background/Purpose: The gold standard for diagnosing lupus nephritis (LN) is renal biopsy, an invasive procedure with associated risks. While traditional biomarkers such as proteinuria and…Abstract Number: 2139 • ACR Convergence 2026
Neighborhood Deprivation as a Risk Factor for Progression to End-Stage Kidney Disease in ANCA-Associated Vasculitis: Experiences from a Large Rural Tertiary Care Rheumatology Referral Center
Background/Purpose: ANCA-associated vasculitis (AAV) is a systemic rheumatic disease whose morbidity is dominated by irreversible organ damage. While racial and ethnic disparities in AAV outcomes…Abstract Number: 1007 • ACR Convergence 2026
Non-Responder Status and Biopsy Chronicity in Lupus Nephritis Associate with Markers of Senescence and Hypoxia Across Kidney Cell Types
Background/Purpose: Lupus nephritis (LN) is a severe and common complication of systemic lupus erythematosus (SLE), associated with worse long-term outcomes and increased mortality. Despite current…Abstract Number: 1439 • ACR Convergence 2026
Disease activity and long-term kidney function trajectories in rheumatoid arthritis: a Japanese nationwide registry cohort study using the NinJa database
Background/Purpose: Previous studies from the United States and Taiwan have shown that patients with rheumatoid arthritis (RA) have a higher risk of developing chronic kidney…
